Tomáš Bolek

Dr. Tomáš Bolek

Department of Internal Medicine I, Jesseniuss Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPMartin Jozef Péč
Martin Jozef Péč
JBJakub Benko
Jakub Benko
JJJakub Jurica
Jakub Jurica
MPMonika Péčová
Monika Péčová
MSMarek Samec
Marek Samec
MMMarián Mokáň
Marián Mokáň
Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence. PCSK9 inhibitors have proven to be a valuable and practical resource for lowering the LDL cholesterol of many patients in recent years. Their inhibitory effect on atherosclerosis progression seems to be driven not just by lipid metabolism modification but also by LDL-independent mechanisms. We review the effect of PCSK9 inhibitors on various mechanisms involving platelet activation, inflammation, endothelial dysfunction, and the resultant clot formation. The main effectors of PCSK9 activation of platelets are CD36 receptors, lipoprotein(a), oxidised LDL particles, tissue factor, and factor VIII. Many more molecules are under investigation, and this area of research is growing rapidly.

13 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LSLucia Stanciakova
Lucia Stanciakova
KBKristina Brisudova
Kristina Brisudova
ISIngrid Skornova
Ingrid Skornova
TBTomáš Bolek
Tomáš Bolek
MSMatej Samos
Matej Samos
JSJuraj Sokol
Juraj Sokol
Venous thromboembolism (VTE) represents one of the leading causes of death during pregnancy. The greatest risk for it is the presence of medical or family history of VTE, stillbirth, cesarean section and selected thrombophilia. Appropriate thromboprophylaxis has the potential to decrease the risk of VTE in at-risk pregnant patients by 60–70%. Based on this, the authors reviewed the PubMed, Web of Science and Scopus databases to identify the possibilities of thromboprophylaxis in pregnant patients with a high risk of VTE. Moreover, they summarized its management in specific situations, such as cesarean delivery or neuraxial blockade. Currently, low-molecular-weight heparins (LMWH) are the preferred drugs for anticoagulant thromboprophylaxis in the course of pregnancy and postpartum due to easy administration and a lower rate of adverse events.

19 January 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MSMatej Samos
Matej Samos
ISIngrid Skornova
Ingrid Skornova
TBTomáš Bolek
Tomáš Bolek
LSLucia Stanciakova
Lucia Stanciakova
BKBarbora Korpallová
Barbora Korpallová
MMMarián Mokáň
Marián Mokáň
Platelets play crucial role in acute vascular atherosclerotic diseases, including myocardial infarction and stroke. Additionally, platelet aggregation is a key target of antiplatelet agents, forming the keystone of pharmacotherapy of various atherosclerotic cardiovascular diseases. Thromboelastography and thromboelastometry, representing currently available viscoelastic hemostatic assays (VHA), are designed as whole blood, real-time analyzers of clot formation and clot resolution. These assays could, in theory, overcome some limitations of currently available platelet function testing assays. This article reviews the current experience with the use of VHA for platelet function testing and for monitoring of the response to antiplatelet therapy.

Verified
Journal Article
Open access
PDF file
TBTomáš Bolek
Tomáš Bolek
MSMatej Samos
Matej Samos
JJJakub Jurica
Jakub Jurica
LSLucia Stanciakova
Lucia Stanciakova
MPMartin Péč
Martin Péč
PKPeter Kubisz
Peter Kubisz
The coronavirus SARS-CoV2 disease (COVID-19) is connected with significant morbidity and mortality (3.4%), disorders in hemostasis, including coagulopathy, activation of platelets, vascular injury, and changes in fibrinolysis, which may be responsible for an increased risk of thromboembolism. Many studies demonstrated relatively high rates of venous and arterial thrombosis related to COVID-19. The incidence of arterial thrombosis in severe/critically ill intensive care unit–admitted COVID-19 patients appears to be around 1%. There are several ways for the activation of platelets and coagulation that may lead to the formation of thrombi, so it is challenging to make a decision about optimal antithrombotic strategy in patients with COVID-19. This article reviews the current knowledge about the role of antiplatelet therapy in patients with COVID-19.

19 December 2025 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
TBTomáš Bolek
Tomáš Bolek
PTPetra Turňová
Petra Turňová
SJSvetlana Janošova
Svetlana Janošova
MPMartin Jozef Péč
Martin Jozef Péč
ISIvana Ságová
Ivana Ságová
MSMatej Samos
Matej Samos

28 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMatej Samos
Matej Samos
TBTomáš Bolek
Tomáš Bolek
LSLucia Stanciakova
Lucia Stanciakova
MPMartin Péč
Martin Péč
KBKristina Brisudova
Kristina Brisudova
PKPeter Kubisz
Peter Kubisz
Direct oral anticoagulants (DOAC) are currently the drug of choice for drug prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). However, repeated ischemic stroke or systemic embolism and bleeding while on DOAC is still a challenging clinical phenomenon in the management of future long-term anticoagulation. It is not known whether tailoring the DOAC therapy to achieve optimal therapeutic drug levels could improve the clinical course of DOAC therapy. To be able to tailor the therapy, it is necessary to have a valid laboratory method for DOAC level assessment, to be aware of factors influencing DOAC levels and to have clinical options to tailor the treatment. Furthermore, the data regarding clinical efficacy/safety of tailored DOAC regimes are still lacking. This article reviews the current data on tailored direct oral anticoagulation in patients with AF.